Physician profile
Melissa D Johnson
NPI 1548284896
$2,061.13
in general payments reported to CMS, 2019-2025
24 companies · $407 in 2025
The $407 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $477 · 2020: $196 · 2021: $137 · 2022: $182 · 2023: $328 · 2024: $334 · 2025: $407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,032 · Entertainment: $20.03 · Education: $16.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,032.39 |
| Entertainment | $20.03 |
| Education | $16.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $696.97 | 2021-2025 | |
| Pfizer INC. | $192.71 | 2019-2025 | |
| Lilly USA, LLC | $167.07 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Janssen Pharmaceuticals, INC | $163.38 | 2019-2024 | Xarelto |
| Novo Nordisk INC | $160.19 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $121.77 | 2019-2025 | Evenity, Prolia, Repatha |
| Astrazeneca Pharmaceuticals LP | $99.67 | 2019-2025 | Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.24 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $49.92 | 2019-2025 | Trintellix |
| Glaxosmithkline, LLC. | $47.03 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $38.12 | 2020 | |
| Allergan, INC. | $38.10 | 2020 | |
| Boston Scientific Corporation | $30.35 | 2024 | Bodyguardian |
| Amarin Pharma, INC. | $22.63 | 2019 | |
| Optos, INC. | $20.03 | 2023 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Array Biopharma INC | $19.39 | 2025 | Xtandi, Braftovi, Talzenna |
| Phadia US INC. | $19.16 | 2025 | Immunocap |
| Adlon Therapeutics L.P. | $19.05 | 2019 | |
| Abbott Laboratories | $17.95 | 2019 | |
| Sanofi Pasteur INC. | $16.54 | 2019 | |
| Phathom Pharmaceuticals, INC. | $15.77 | 2024 | Voquezna |
| Corium, LLC | $15.42 | 2023 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $14.07 | 2024 | Eliquis |
| Novartis Pharmaceuticals Corporation | $13.60 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.